Internal Medicine, Nephrology · McAlester, OK
NPI
1194855528
Since 2007
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
2
Medicare group memberships
Hospitals
6
Hospital affiliations
4 E Clark Bass Blvd Ste 203
McAlester, OK, 74501
Phone (918) 420-1238
Groups this clinician bills Medicare through
Medicare paid, 2024
$308K
4,169 services
Medicare patients, 2024
589
Average age 72
Drug cost, 2024
$784K
1,547 prescriptions
Company payments, 2025
$1,199
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul T Dreyer was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 1,698 times for 75 patients. In total Paul T Dreyer billed 4,169 services in 71 codes, and Medicare paid $308K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-23.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,698 | 75 | $0.10 | $172 |
| 99232 Hospital E&M - Subsequent | Facility | 983 | 273 | $60.96 | $60K |
| 90960 ESRD Related Services (not dialysis) | Office | 357 | 51 | $272.47 | $97K |
| 99223 Hospital E&M - Initial | Facility | 114 | 110 | $133.26 | $15K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 96 | 76 | $12.68 | $1,217 |
| 99233 Hospital E&M - Subsequent | Facility | 87 | 56 | $92.27 | $8,027 |
| 99214 Office E&M - Established | Office | 80 | 59 | $64.44 | $5,155 |
| 99213 Office E&M - Established | Office | 74 | 66 | $53.58 | $3,965 |
| 36901 Angiography | Office | 40 | 37 | $516.09 | $21K |
| 99222 Hospital E&M - Initial | Facility | 38 | 36 | $97.02 | $3,687 |
| 36415 Venipuncture Blood Collection | Office | 33 | 20 | $8.65 | $285 |
| 36902 A-V Fistula PCI | Office | 31 | 24 | $881.14 | $27K |
| 80053 Clinical Chemistry | Office | 27 | 17 | $10.35 | $279 |
| 82043 Clinical Chemistry | Office | 24 | 14 | $5.66 | $136 |
| 82570 Clinical Chemistry | Office | 24 | 14 | $5.08 | $122 |
By year: 2022 $376K for 7,619 services; 2023 $327K for 5,705 services; 2024 $308K for 4,169 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 33 | 20 | $8.65 | $285 |
| 80053 Clinical Chemistry | 27 | 17 | $10.35 | $279 |
| 82043 Clinical Chemistry | 24 | 14 | $5.66 | $136 |
| 82570 Clinical Chemistry | 24 | 14 | $5.08 | $122 |
| 84156 Clinical Chemistry | 22 | 12 | $3.60 | $79.2 |
| 81003 Clinical Chemistry | 19 | 18 | $2.10 | $39.84 |
Medicare prescription drug claims, 2024
In 2024, the drug Paul T Dreyer prescribed most often to Medicare patients was Farxiga (Dapagliflozin Propanediol), with 86 prescriptions and refills. In total Paul T Dreyer wrote 1,547 Medicare prescriptions that cost $784K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Farxiga Dapagliflozin Propanediol | 86 | 256 | 25 | $140K |
| Amlodipine Besylate Generic | 70 | 213 | 24 | $459 |
| Hydralazine Hcl Generic | 58 | 146 | 17 | $880 |
| Allopurinol Generic | 58 | 174 | 18 | $784 |
| Nifedipine Er Nifedipine | 56 | 152 | 16 | $1,507 |
| Losartan Potassium Generic | 48 | 142 | 19 | $391 |
| Potassium Citrate Er Potassium Citrate | 48 | 125 | 14 | $7,589 |
| Indapamide Generic | 46 | 139 | 15 | $734 |
| Furosemide Generic | 46 | 132 | 22 | $359 |
| Clonidine Hcl Generic | 44 | 102 | 15 | $446 |
| Sevelamer Carbonate Generic | 42 | 68 | 16 | $40K |
| Tramadol Hcl Generic | 39 | 41 | Under 11 | $527 |
| Kerendia Finerenone | 37 | 81 | 11 | $50K |
| Doxazosin Mesylate Generic | 34 | 102 | 14 | $516 |
| Lisinopril Generic | 26 | 78 | Under 11 | $203 |
Brand drugs: - claims; generic drugs: 1,211 claims; opioid claims: 40.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul T Dreyer $1,199 ($1,199 in general payments such as food, travel and fees) from 20 companies. The largest payer was Amgen Inc. with $264.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 9 | $264 |
| Calliditas Therapeutics US Inc. | 8 | $178 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $77.05 |
| GlaxoSmithKline, LLC. GSK | 4 | $74.9 |
| OPKO Pharmaceuticals, LLC | 3 | $66.37 |
| Ardelyx, Inc. ARDX | 3 | $64.74 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 2 | $51.82 |
| Mallinckrodt Hospital Products Inc. | 2 | $51.56 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $49.46 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $48.88 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.